Unichem Laboratories receives FDA approval on asthma drug
Unichem Laboratories has received the final go ahead from FDA to manufacture the generic version Merck Sharp & Dohme Corp's Singulair tablets. These tablets are used in the treatment of asthma.
Drug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and chronic treatment of asthma, as confirmed by the PTI.
"The company has received ANDA approval for Motelukast Sodium tablets from the United States Food and Drug Administration (USFDA)," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Goa plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Singulair tablets in the strength of 10 mg, Unichem said.
Montelukast is used for prevention and chronic treatment of asthma, prevention of exercise induced bronchoconstriction and allergic rhinitis, it added.
Drug firm Unichem Laboratories has received approval from the US health regulator for its Montelukast Sodium tablets used in prevention and chronic treatment of asthma, as confirmed by the PTI.
"The company has received ANDA approval for Motelukast Sodium tablets from the United States Food and Drug Administration (USFDA)," Unichem Laboratories said in a filing to BSE.
The product will be commercialised from the company's Goa plant, it added.
The product is generic version of Merck Sharp & Dohme Corp's Singulair tablets in the strength of 10 mg, Unichem said.
Montelukast is used for prevention and chronic treatment of asthma, prevention of exercise induced bronchoconstriction and allergic rhinitis, it added.
Next Story
